{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:41:39Z","timestamp":1762375299592,"version":"3.35.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.bcp.2008.10.008","type":"journal-article","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T08:11:32Z","timestamp":1225440692000},"page":"310-321","source":"Crossref","is-referenced-by-count":7,"title":["The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells"],"prefix":"10.1016","volume":"77","author":[{"given":"Sandra A.","family":"Bright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom F.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Campiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Butini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Brindisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Meegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Clive","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela M.","family":"Zisterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2008.10.008_bib1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukaemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2001.1.87","article-title":"Chronic myelogenous leukemia","volume":"1","author":"Druker","year":"2001","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bcp.2008.10.008_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2008.10.008_bib4","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukaemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib5","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bcp.2008.10.008_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571 and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib8","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cncr.21590","article-title":"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2008.10.008_bib10","first-page":"2976","article-title":"Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells","volume":"8","author":"Yu","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib11","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib12","first-page":"2118","article-title":"Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr\/Abl+ human myeloid leukemia cells","volume":"63","author":"Yu","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib13","first-page":"188","article-title":"Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells","volume":"62","author":"Yu","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib14","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-05-2282","article-title":"Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1\/2 inhibitors in Bcr\/abl+ leukemia cells sensitive and resistant to imatinib mesylate","volume":"12","author":"Nguyen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0074-7696(08)62312-8","article-title":"Cell death: the significance of apoptosis","volume":"68","author":"Wyllie","year":"1980","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.bcp.2008.10.008_bib16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(86)90004-8","article-title":"Genetic control of programmed cell death in the nematode C. elegans","volume":"44","author":"Ellis","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2008.10.008_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/MMBR.64.4.821-846.2000","article-title":"Proteases for cell suicide: functions and regulation of caspases","volume":"64","author":"Chang","year":"2000","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.bcp.2008.10.008_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yexcr.2005.10.003","article-title":"Characterization of a serine protease-mediated cell death program activated in human leukemia cells","volume":"312","author":"O\u2019Connell","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0925-4439(03)00128-5","article-title":"Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by the pyrrolo-1,5-benzoxazepine, PBOX-21","volume":"1639","author":"Mulligan","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2008.10.008_bib20","first-page":"1357","article-title":"The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo","volume":"14","author":"Greene","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bcp.2008.10.008_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.106.116640","article-title":"STI-571 enhances the apoptotic efficacy of PBOX-6, a novel microtubule targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells","volume":"321","author":"Greene","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.10.008_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3565(24)39202-X","article-title":"Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents","volume":"293","author":"Zisterer","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.10.008_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29659-2","article-title":"Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl","volume":"296","author":"Mc Gee","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.10.008_bib24","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1021\/jm960251b","article-title":"Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific \u201cperipheral-type\u201d benzodiazepine receptor ligands","volume":"39","author":"Campiani","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2008.10.008_bib25","first-page":"3976","article-title":"Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis","volume":"53","author":"Kaufmann","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib26","article-title":"Caspase inhibitor BD-fmk distinguishes transforming growth factor beta-induced apoptosis from growth inhibition","volume":"9","author":"Brown","year":"1998","journal-title":"Cell Growth Differ"},{"issue":"January (1)","key":"10.1016\/j.bcp.2008.10.008_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/modpathol.3800039","article-title":"Caspase-3 activation in systemic anaplastic large-cell lymphoma","volume":"17","author":"Drakos","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bcp.2008.10.008_bib28","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0006-2952(03)00499-4","article-title":"In the cut and thrust of apoptosis, serine proteases come of age","volume":"66","author":"Stenson-Cox","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.10.008_bib29","doi-asserted-by":"crossref","first-page":"20049","DOI":"10.1074\/jbc.274.29.20049","article-title":"Suicidal tendencies: apoptotic cell death by caspase family proteinases","volume":"274","author":"Wolf","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2008.10.008_bib30","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"10","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib31","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib32","first-page":"4499","article-title":"Characterization of a K562 multidrug-resistant cell line","volume":"49","author":"Yanovich","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL","volume":"191","author":"Horita","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2008.10.008_bib34","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood.V97.9.2846","article-title":"Down-regulation of interleukin-3\/granulocyte-macrophage colony-stimulating factor receptor beta-chain in Bcr-Abl (+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after Bcr-Abl inhibition","volume":"97","author":"Donato","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib35","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1124\/mol.105.015826","article-title":"Apoptosis induced by a new member of saponin family is mediated through caspase-8-dependent cleavage of Bcl-2","volume":"68","author":"Zhu","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2008.10.008_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00008390-200304000-00007","article-title":"Anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to bcl-2 cleavage and bak expression","volume":"13","author":"Kamei","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/excr.2000.5036","article-title":"Apoptosis of Mo7e leukemia cells is associated with the cleavage of Bcl-2 into a shortened fragment that is not functional for heterodimerization with Bcl-2 and Bax","volume":"261","author":"Lin","year":"2000","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib38","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2008.10.008_bib39","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","article-title":"Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells","volume":"24","author":"Essafi","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2008.10.008_bib40","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/sj.leu.2403944","article-title":"CD44 ligation induces apoptosis via caspase- and serine protease-dependent pathways in acute promyelocytic leukemia cells","volume":"19","author":"Maquarre","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2008.10.008_bib41","doi-asserted-by":"crossref","first-page":"26425","DOI":"10.1074\/jbc.M414569200","article-title":"Caspase-dependent and -independent activation of acid sphingomyelinase signaling","volume":"280","author":"Rotolo","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2008.10.008_bib42","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1182\/blood-2003-05-1605","article-title":"A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity","volume":"103","author":"Okada","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2008.10.008_bib43","first-page":"2169","article-title":"Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors","volume":"26","author":"Radujkovic","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2008.10.008_bib44","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.bcp.2005.02.021","article-title":"Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR\/ABL-positive cell lines","volume":"69","author":"Miyoshi","year":"2005","journal-title":"Biochem Pharmacol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295208007132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295208007132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T12:56:47Z","timestamp":1738501007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295208007132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0006295208007132"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2008.10.008","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}